Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study - 20/02/20
Doi : 10.1016/j.jaad.2019.12.070
Ellen J. Kim, MD a, ⁎ 
, Larisa Geskin, MD b, Joan Guitart, MD c, Christiane Querfeld, MD d, Michael Girardi, MD e, Amy Musiek, MD f, David R. Mink, MS g, Michael J. Williams, PhD g, James T. Angello, PharmD h, William L. Bailey, PharmD h
, Larisa Geskin, MD b, Joan Guitart, MD c, Christiane Querfeld, MD d, Michael Girardi, MD e, Amy Musiek, MD f, David R. Mink, MS g, Michael J. Williams, PhD g, James T. Angello, PharmD h, William L. Bailey, PharmD h a Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
b Department of Dermatology, Columbia University, New York, New York
c Department of Dermatology, Northwestern University, Chicago, Illinois
d Division of Dermatology, City of Hope, Duarte, California
e Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
f Division of Dermatology, Washington University in St. Louis School of Medicine, Saint Louis, Missouri
h ICON Commercialization & Outcomes, Dublin, Ireland
g Helsinn Therapeutics (US), Inc, Iselin, NJ
∗Reprint requests: Ellen J. Kim, MD, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Rm 721, 7th Floor-South Tower, Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104Department of DermatologyPerelman School of Medicine at the University of PennsylvaniaRm 721, 7th Floor-South Tower, Perelman Center for Advanced Medicine3400 Civic Center BlvdPhiladelphiaPA19104
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Thursday 20 February 2020
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
| Funding sources: This study was supported by Helsinn Therapeutics (US), Inc. Role of the funder: Design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review, or approval of the manuscript. All authors made the decision to submit the manuscript for publication. |
|
| Conflicts of interest: Dr Kim has received grant funding from Helsinn, Galderma, Kyowa Kirin, Medimmune, and Soligenix; consulted for Helsinn and the PROVe Scientific Committee, Galderma, and WebMD; and served on an advisory board for Seattle Genetics. Dr Geskin has received grant funding and has consulted for Helsinn. Dr Guitart has received grant funding and had consulted for Helsinn, received grant funding from Galderma, Medivir, and Soligenix, and has consulted for Miragen and LEO Pharma. Dr Querfeld has consulted for Miragen, Helsinn, Mallinckrodt, Medivir, and Kyowa Kirin and received grant funding from STOP Cancer, the Leukemia & Lymphoma Society, Trillium, and Celgene Corp. Dr Girardi has consulted for Helsinn, Mallinckrodt, Transimmune, and Sanofi and received grant funding from Helsinn, Soligenix, and AbbVie. Dr Musiek has received grant funding and consulted for Helsinn, Elorac, Kyowa Kirin, Soligenix, and Pfizer; served on advisory board for Helsinn, Kyowa Kirin, and Seattle Genetics, and served on a speakers bureau for Helsinn. Mr Mink and Dr Williams are employed by ICON Commercialization & Outcomes. Dr Angello and Dr Bailey are employed by Helsinn Therapeutics (US), Inc. |
|
| IRB approval status: Reviewed and approved where applicable. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?